PMID- 27903846
OWN - NLM
STAT- MEDLINE
DCOM- 20170724
LR  - 20181113
IS  - 2058-7384 (Electronic)
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 30
IP  - 1
DP  - 2017 Mar
TI  - Cytokine profiles of tumor supernatants in invasive ductal cancer and 
      fibroadenoma of the breast and its relationship with VEGF-A expression in the 
      tumors.
PG  - 83-88
LID - 10.1177/0394632016681306 [doi]
AB  - Interrelations between cytokines, produced by invasive ductal carcinoma (IDC) and 
      fibroadenoma (FA) of the breast, and angiogenic growth factor VEGF-A, expressed 
      in IDC and FA, were investigated. The analysis of the cytokine profiles of IDC 
      and FA was performed by cultivation of tumor biopsy specimens in vitro. Testing 
      of the cytokine-producing reserve of the tumors for production of VEGF-A was 
      conducted by culturing samples of IDC and FA in a medium containing polyclonal 
      activator (a complex of phytohemagglutinin, concanavalin A, and 
      lipopolysaccharide). Levels of cytokines and growth factors (IL-2, IL-6, IL-8, 
      IL-10, IL-17, IL-18, IL-1beta, IL-1Ra, TNF-alpha, IFN-gamma, G-CSF, GM-CSF, VEGF-A) and 
      MCP-1 (monocyte chemoattractant protein-1) in tumor supernatants were determined 
      by an ELISA. Expression of VEGF-A was analyzed in tumor biopsy specimens by 
      immunohistochemical analysis. In the IDC supernatants, the concentrations of 
      IL-17, IL-18, and IFN-gamma were higher and the concentrations of IL-10 and MCP-1 
      were lower in comparison with the FA supernatants. We observed negative 
      correlations between the macrophage infiltration and VEGF-A concentration in the 
      IDC supernatants (r = -0.508; P = 0.011) and between VEGF-A expression and the 
      IDC vascularization degree (r = -0.423, P = 0.039). Spontaneous expression of 
      VEGF-A in samples of IDC significantly exceeded the VEGF-A expression in FA. 
      There was no difference between IDC and FA in VEGF-A expression after treatment 
      with the polyclonal activators. Our results indicate that greater malignancy may 
      have a paradoxical effect that is controlled by cytokines and characterized by 
      weakening of tumor angiogenesis during overproduction of VEGF-A. These findings 
      point to complex mechanisms of positive and negative regulation of tumor 
      angiogenesis by cytokines that are produced by the tumor and by cells in its 
      microenvironment, whose cytokine profiles may change at different stages of tumor 
      progression.
FAU - Autenshlyus, Alexander I
AU  - Autenshlyus AI
AD  - 1 Novosibirsk State Medical University, Novosibirsk, Russia.
AD  - 2 Institute of molecular biology and Biophysics, Novosibirsk, Russia.
FAU - Arkhipov, Sergey A
AU  - Arkhipov SA
AD  - 1 Novosibirsk State Medical University, Novosibirsk, Russia.
AD  - 2 Institute of molecular biology and Biophysics, Novosibirsk, Russia.
FAU - Kunts, Tatiana A
AU  - Kunts TA
AD  - 1 Novosibirsk State Medical University, Novosibirsk, Russia.
FAU - Marinkin, Igor O
AU  - Marinkin IO
AD  - 1 Novosibirsk State Medical University, Novosibirsk, Russia.
FAU - Mikhailova, Elena S
AU  - Mikhailova ES
AD  - 1 Novosibirsk State Medical University, Novosibirsk, Russia.
AD  - 2 Institute of molecular biology and Biophysics, Novosibirsk, Russia.
FAU - Karpukhina, Xenia V
AU  - Karpukhina XV
AD  - 2 Institute of molecular biology and Biophysics, Novosibirsk, Russia.
FAU - Varaksin, Nikolay A
AU  - Varaksin NA
AD  - 3 AO Vector-best, Novosibirsk, Russia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20170124
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (Cytokines)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Breast Neoplasms/*metabolism
MH  - Carcinoma, Ductal, Breast/*metabolism
MH  - Cytokines/*metabolism
MH  - Female
MH  - Fibroadenoma/*metabolism
MH  - Humans
MH  - Middle Aged
MH  - Vascular Endothelial Growth Factor A/*metabolism
PMC - PMC5806784
OTO - NOTNLM
OT  - breast
OT  - cancer
OT  - cytokines
OT  - fibroadenoma
COIS- Declaration of conflicting interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2016/12/03 06:00
MHDA- 2017/07/25 06:00
PMCR- 2017/03/01
CRDT- 2016/12/02 06:00
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2017/07/25 06:00 [medline]
PHST- 2016/12/02 06:00 [entrez]
PHST- 2017/03/01 00:00 [pmc-release]
AID - 0394632016681306 [pii]
AID - 10.1177_0394632016681306 [pii]
AID - 10.1177/0394632016681306 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2017 Mar;30(1):83-88. doi: 
      10.1177/0394632016681306. Epub 2017 Jan 24.